Novo Nordisk targets type 2 diabetes mAbs in Xoma licensing deal

By Dan Stanton contact

- Last updated on GMT

Photo - designer491/iStock
Photo - designer491/iStock

Related tags: Insulin

Novo Nordisk has licensed the rights to Xoma’s monoclonal antibody insulin receptor activators in a deal potentially worth over $290m (€272m).

The Danish Biopharma firm will pay Xoma Corporation $5m upfront for the global development and commercialisation rights to its XMetA programme of mAb candidates, but the total cost could add $290m in development and regulatory milestone payments.

The XMetA programme was instigated by Xoma to help develop a new way of treating type 2 diabetes using mAbs that are partial agonists of the insulin receptor, yet are structurally unrelated to insulin and bind at a different site without interfering with insulin binding.

“In vitro data have shown the lead compound in the XMetA program mimics insulin's glucose regulatory functions, but none of its mitogenic actions,”​ said Xoma’s CMO Paul Rubin.

“Most recently, weekly subcutaneous treatment with the lead molecule in the XMetA program in a clinically relevant animal model of diabetes resulted in robust decreases in hyperglycemia without hypoglycemia and weight gain, along with a significant absolute reduction in HbA1c of 1.2 percent.”

As for the deal, Novo Nordisk spokesperson Katrine Rud von Sperling told this publication it “is a licensing agreement with all responsibilities transferred to Novo Nordisk,” ​though could not divulge any details as to the manufacturing of these candidates at this time.

Berkeley, California-based Xoma recently sold its GMP antibody production site​ to immunology firm Agenus for $5m, saying the divestiture was part of a plan to reduce headcount and transform the firm into an endocrine company.

Related topics: Pipelines, Bio Developments

Related news

Show more

Follow us

Products

View more

Webinars